Keywords: متابولیسم ضعیف; pharmacokinetics; obesity; pediatrics; proton pump inhibitors; AE; Adverse event; AUC; Area under the concentration time curve; AUCinf; AUC from time zero to infinity; AUClast; AUC from time zero to the time of the last measurable concentration; BMI; Body
مقالات ISI متابولیسم ضعیف (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: متابولیسم ضعیف; Cl; clearance; CYP; cytochrome P450; ECG; electrocardiogram; ECMO; extracorporeal membrane oxygenation; EM; extensive metabolizer; ICU; intensive care unit; IM; intermediate metabolizer; MR; metabolic ratio; PM; poor metabolizer; t1/2; elimination half-li
Keywords: متابولیسم ضعیف; ACS; acute coronary syndrome; PCI; percutaneous coronary intervention; DNA; deoxyribonucleic acid; SNPs; single nucleotide polymorphisms; CV death; cardiovascular death; MI; myocardial infarction; EM; extensive metabolizer; IM; intermediate metabolizer; P
Keywords: متابولیسم ضعیف; AUC; area under the curve; CPIC; Clinical Pharmacogenetics Implementation Consortium; CYP; cytochrome P450; EM; extensive metabolizer; FDA; US Food and Drug Administration; OCD; obsessive-compulsive disorder; PM; poor metabolizer; QIDS-C16; Quick Inventor
Is CYP2D6 phenotype predictable from CYP2D6 genotype?
Keywords: متابولیسم ضعیف; CNV; copy number variation; CYP; cytochrome P450; EM; extensive metabolizer; IM; intermediate metabolizer; PCR; polymerase chain reaction; PM; poor metabolizer; SNP; single nucleotide polymorphism; UM; ultra-rapid metabolizer; CYP2D6 genotype; Genetic pol
CYP2D6 (C2850T, G1846A, C100T) polymorphisms, haplotypes and MDR analysis in predicting coronary artery disease risk in north-west Indian population: A case-control study
Keywords: متابولیسم ضعیف; μl; microlitre; A; adenine; BMI; body mass index; bp; basepair; C; cytosine; CAD; coronary artery disease; CI; confidence intervals; CNS; central nervous system; CVC; cross validation consistency; CYP2D6; cytochrome P450 2D6; EDTA; ethylenediaminetetra a
Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction
Keywords: متابولیسم ضعیف; CAR; constitutive androstane receptor; CI; confidence interval; CYP; cytochrome P450; EM; extensive metabolizer; GAPDH; glyceraldehyde 3-phosphate dehydrogenase; GR; glucocorticoid receptor; IM; intermediate metabolizer; PCR; polymerase chain reaction; PM
Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics
Keywords: متابولیسم ضعیف; ADH; alcohol dehydrogenase; CDC; Centers for Disease Control and Prevention; CYP; cytochrome P450; del; deletion; EDDP; 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine; EM; extensive metabolizer; EMDP; 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline; FDA; Food and
Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes
Keywords: متابولیسم ضعیف; RO; receptor occupancy; EPS; extrapyramidal symptoms; PK; pharmacokinetic; PD; pharmacodynamic; EM; extensive metabolizer; IM; intermediate metabolizer; PM; poor metabolizer; PBPKPD; physiology-based pharmacokinetic and pharmacodynamic; P-gp; P-glycoprote
Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels
Keywords: متابولیسم ضعیف; CYP2D6; Luminex; Activity score; Risperidone; Autism spectrum disorder; CYP2D6; Cytochrome P450 2D6; PM; poor metabolizer; IM; intermediate metabolizer; EM; extensive metabolizer; UM; ultra-rapid metabolizer; ASD; autism spectrum disorder; F; function; DF
Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery
Keywords: متابولیسم ضعیف; 16; 23.1; BB; β-blocker; CABG; coronary artery bypass grafting; CI; confidence interval; EuroSCORE; European System for Cardiac Operative Risk Evaluation score; IPW; inverse probability weighting; OR; odds ratio; PM; poor metabolizer;
Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population
Keywords: متابولیسم ضعیف; bp; base pair(s); CYP; cytochrome P450; DNA; deoxyribonucleic acid; EM; extensive metabolizer; LD; linkage disequilibrium; LOD; log odds score; MAF; minor allele frequency; min; minute; PCR; Polymerase Chain Reaction; PM; poor metabolizer; s; second; SNP;
Association of CYP2C19 Polymorphisms and Lansoprazole-Associated Respiratory Adverse Effects in Children
Keywords: متابولیسم ضعیف; CYP; Cytochrome P450; EM; Extensive metabolizer; PM; Poor metabolizer; PPI; Proton pump inhibitor; SNP; Single nucleotide polymorphism; ST; Sore throat; URI; Upper respiratory tract infection; WT; Wild type;
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Keywords: متابولیسم ضعیف; Biotransformation; Cytochrome P450 monooxygenase; NADPH:cytochrome P450 reductase; Pharmacogenetics; Polymorphism; Xenobiotic; ADME; absorption, distribution, metabolism, excretion; ADR; adverse drug reaction; AhR; aromatic hydrocarbon receptor; CNV; copy
A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine
Keywords: متابولیسم ضعیف; CYP2D6; CYP2C19; Venlafaxine; Poor metabolizer; Drug poisoning; Mechanistic pharmacokinetic simulation
Ability of Rabeprazole to Prevent Gastric Mucosal Damage From Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 Genotype
Keywords: متابولیسم ضعیف; Stomach; PPI; Drug Interactions; Cardiovascular; AC; aspirin and clopidogrel; ARU; aspirin reaction unit; CYP2C19; S-mephenytoin 4â²-hydroxylase; GSRS; Gastrointestinal Symptom Rating Scale; IM; intermediate metabolizer; IPA; inhibition of platelet aggre
Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With Atherosclerosis
Keywords: متابولیسم ضعیف; Proton-Pump Inhibitor; Plavix; CYP2C19; Drug Interactions; hetEM; heterogeneous extensive metabolizer; homEM; homogeneous extensive metabolizer; ITT; intention to treat; NSAID; nonsteroidal anti-inflammatory drug; PM; poor metabolizer; PPA; percentage of
Treatment Considerations for Patients With Neuropathic Pain and Other Medical Comorbidities
Keywords: متابولیسم ضعیف; ADR; adverse drug reaction; BP; blood pressure; CKD; chronic kidney disease; CYP; cytochrome P450; ECG; electrocardiogram; EM; extensive metabolizer; GFR; glomerular filtration rate; MI; myocardial infarction; NP; neuropathic pain; NSAID; nonsteroidal ant
Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection
Keywords: متابولیسم ضعیف; CYP2C19; Helicobacter pylori; Pharmacogenomics; Proton pump inhibitor; Rapid metabolizer; Intermediate metabolizer; Poor metabolizer;
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
Keywords: متابولیسم ضعیف; Cytochrome P450 3A4; P450 2C19; Poor metabolizer; NMR; LC/MS; Hydroxylation
The AmpliChip CYP450 Test: Principles, Challenges, and Future Clinical Utility in Digestive Disease
Keywords: متابولیسم ضعیف; ADR; adverse drug reaction; IBS-C; constipation-predominant irritable bowel syndrome; CYP450; cytochrome P450; IBS-D; diarrhea-predominant irritable bowel syndrome; EM; extensive metabolizer; GERD; gastroesophageal reflux disease; IBS; irritable bowel syn
Gastroduodenal Disease, Helicobacter pylori, and Genetic Polymorphisms
Keywords: متابولیسم ضعیف; cagPAI; cag pathogenicity island; DU; duodenal ulcer; EM; extensive metabolizer; HLA; human leukocyte antigen; iceA; induced by contact with epithelium; IL; interleukin; MHC; major histocompatibility complex; PM; poor metabolizer; PPI; proton pump inhibit
Influence of CYP2C19 Polymorphism and Helicobacter pylori Genotype Determined From Gastric Tissue Samples on Response to Triple Therapy for H pylori Infection
Keywords: متابولیسم ضعیف; CI; confidence interval; 13C-UBT; 13C-urea breath test; CYP2C19; S-mephenytoin 4â²-hydroxylase; DU; duodenal ulcer; GU; gastric ulcer; IM; intermediate metabolizer; MALT; mucosa-associated lymphoid tissue; MIC; minimum inhibitory concentration; PCR; poly
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
Keywords: متابولیسم ضعیف; 5-FU; 5-fluorouracil; 5-HTT; serotonin transporter; 5-HTTLPR; serotonin gene-linked polymorphic region; 6-MP; 6-mercaptopurine; 6-TG; 6-thioguanine; ABCB; ATP-binding cassette (ABC), subfamily B; ACE; angiotensin I converting enzyme (peptidyl-dipeptidase